The assignee ranking behind this landscape covers 100 companies, and it is not a simple top-10 or top-50 cut — it is the full ranked set the dataset returns. The leading assignee holds 233 records, with a taper down to 174 at fifth place and 90 at tenth, so leadership exists but is not a near-monopoly. Roughly three-quarters of all records in scope sit outside the top ten filers, spread across a long tail of companies with smaller portfolios, so checking any single leader's portfolio is not sufficient for a full freedom-to-operate picture.

Filings rose to a peak of 388 in 2020 and have since eased, with complete-year data showing 342 filings in 2021 falling to 230 by 2024, a 33% pullback. Years after 2024 in the raw trend look lower still, but that is expected: publication typically lags actual filing by around 18 months, so the newest years are undercounted and will revise upward as more records publish. Read the 2021-2024 window as the reliable signal, not the tail end of the chart.

Medicinal-preparation claims under IPC class A61K appear on 67.0% of the 6,041 records in scope, making formulation the clear center of gravity, with therapeutic-activity claims (A61P) layered on top of many of the same filings at 28.0%. Microorganism and genetic-engineering claims (C12N), food-adjacent claims (A23L) and sterilisation claims (A61L) each sit around 10%, forming a mid tier. Device-level (A61M) and container-level (A61J) classifications are comparatively thin, at 5.5% and 3.2%, which points to more open claim space around the hardware that delivers a sterile dose rather than the formulation inside it.

The clearest gaps sit outside the dense A61K/A61P formulation core, in branches like fill-volume dosing hardware, container-closure integrity testing, sterile single-use fluid pathways, stability-indicator assay methods and aseptic connector design, all of which carry noticeably thinner IPC coverage in this corpus than formulation claims do. That does not mean these areas are unclaimed, only that claim density is lower, which is where a targeted novelty search is most likely to find room. Any first claim aimed at these branches should be checked specifically against the container- and device-class records rather than the much larger formulation literature.

US20080305161A1, assigned to Pfizer and published in December 2008, covers injectable depot formulations built around a compound such as ziprasidone at a controlled maximum particle size, combined with a carrier and, preferably, at least two surface stabilizers, along with methods of treating psychosis and processes for making the formulation. It is a useful reference point for nanoparticle depot and sustained-release claim drafting because it ties specific particle-size and stabilizer limitations to a named therapeutic use. It does not, on its own, block work using different particle-size ranges, different stabilizer counts, or different carrier chemistries, but any new depot-formulation claim in this space should be checked against its specific limitations before drafting around it.